齐拉西酮合并氯硝西泮治疗精神分裂症激越症状的研究

doi:10.3969/j.issn.1674-490X.2013.04.002

医学研究与教育 ›› 2013, Vol. 30 ›› Issue (4): 5-9.DOI: 10.3969/j.issn.1674-490X.2013.04.002

齐拉西酮合并氯硝西泮治疗精神分裂症激越症状的研究

王健¹,段斐²

1.河北大学，河北保定 071000; 河北省精神卫生中心，河北保定 071000
2.河北大学,河北保定,071000

收稿日期:2016-10-09 修回日期:2016-10-09 出版日期:2013-08-25 发布日期:2013-08-25

Study on ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia

WANG Jian¹,DUAN Fei²

Received:2016-10-09 Revised:2016-10-09 Online:2013-08-25 Published:2013-08-25

摘要/Abstract

摘要： 目的了解齐拉西酮注射液合并氯硝西泮治疗精神分裂症激越症状的疗效和安全性。方法将80例精神分裂症激越症状患者随机分为2组，分别接受肌肉注射齐拉西酮合并氯硝西泮和肌肉注射氟哌啶醇治疗。评价指标包括72 h后简明精神评定量表（BPRS）总分、行为活动评定量表（BARS）和BPRS激越症状亚量表评分的改变；Simpson-Angus锥体外系不良反应评定量表的评分改变等。结果从基线到研究终点BPRS激越症状亚量表评分减少30%以上（>30%）的受试者被判定是有效者，其中齐拉西酮组有效者37例（92.5%），氟哌啶醇组有效者32例（80.0%），两组比较差异无统计学意义（χ2=2.635，P=0.193）。齐拉西酮组锥体外系症状发生1例（2.5%）少于氟哌啶醇组14例（35%）（χ2=13.767， P<0.001）。结论齐拉西酮注射液合并氯硝西泮治疗精神分裂症激越症状疗效和氟哌啶醇注射液相当，锥体外系不良反应比氟哌啶醇轻，安全性较好。

关键词: 齐拉西酮, 氯硝西泮, 精神分裂症, 激越

Abstract: Objective To investigate the efficacy and safety of intramuscular ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia. Methods 80 cases with agitation of schizophrenia patients were randomly divided into 2 groups, were treated with intramuscular ziprasidone combined with clonazepam and haloperidol. The evaluating indicators include the Brief Psychiatric Rating Scale (BPRS) score, behavior rating scale (BARS) and BPRS agitated symptoms subscale scores;Also include Simpson–Angus extrapyramidal side effects Rating Scale. Results From baseline to endpoint the subject BPRS agitation symptoms subscale score reduced more than 30%(>30%) was judged to be effective. The effective subjects of ziprasidone group was 37 cases (92.5%), and 32 cases in haloperidol group (80%).The two groups had no signiifcant difference (χ2=2.635, P=0.193). The extrapyramidal side effects occur in ziprasidone group was 1 cases (2.5%) less than haloperidol group of 14 cases (35%) (χ2=13.767, P<0.001). Conclusion Intramuscular ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia is as efficacy as haloperidol, the extrapyramidal side effects is less than that of haloperidol.

Key words: ziprasidone, clonazepam, schizophrenia, agitation

中图分类号:

R749.3

王健,段斐. 齐拉西酮合并氯硝西泮治疗精神分裂症激越症状的研究[J]. 医学研究与教育, 2013, 30(4): 5-9.

WANG Jian,DUAN Fei. Study on ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia[J]. Medical Reserch and Education, 2013, 30(4): 5-9.

参考文献

[1] 张疆莉, 张建宏, 申彪. 齐拉西酮注射液与氟哌啶醇注射液治疗急性精神分裂症的疗效及安全性比较 [J]. 中国现代药物应用 2010.doi:10.3969/j.issn.1673-9523.2010.12.108
[2] 陈琦, 薄奇静, 迟勇, 赵幸福, 李晓驷, 谭云龙, 杜波, 王传跃, CHEN Qi, BO Qi-jing, CHI Yong, ZHAO Xing-fu, LI Xiao-si, TAN Yun-long, DU Bo, WANG Chuan-yue. 齐拉西酮合并氯硝西泮治疗急性期伴激越精神分裂症患者的对照研究 [J]. 临床精神医学杂志 2012.
[3] 李四冬, 周严俊, 戢秋明, 江凌翔, Li Sidong, Zhou Yanjun, Ji Qiuming, Jiang Lingxiang. 齐拉西酮注射剂与氟哌啶醇注射剂治疗精神分裂症急性期患者的对照研究 [J]. 上海精神医学 2010.doi:10.3969/j.issn.1002-0829.2010.04.011
[4] 陈光财, 邓方渝, 王德燧, 许可, CHEN Guang-cai, DENG Fang-yu, WANG De-sui, XU Ke. 齐拉西酮注射液治疗精神分裂症急性期的对照研究 [J]. 安徽医药 2010.doi:10.3969/j.issn.1009-6469.2010.09.041
[5] Brook S. [J]. The journal of clinical psychiatry 2003.
[6] Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. Treatment of behavioral emergencies 2005. [J]. Journal of psychiatric practice 2005, Suppl.1(Suppl.1).
[7] San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. [J]. Current pharmaceutical design 2005, 19(19).
[8] Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. [J]. Clinical therapeutics 2002, 1(1).
[9] Zhang, H., Wang, G., Zhao, J., Xie, S., Xu, X., Shi, J., Deng, H., Li, K., Gao, C., Wang, X., Vanderburg, D., Pan, S., Tang, H., Shu, L., Karayal, O.N.. Intramuscular ziprasidone versus haloperidol for managing agitation in chinese patients with schizophrenia [J]. Journal of clinical psychopharmacology 2013, 2(2).
[10] Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. [J]. The journal of clinical psychiatry 2008, Suppl.1(Suppl.1).
[11] 舒良. 精神分裂症防治指南 [M]. 北京:北京大学医学出版社 2007.
[12] JANGRO W C, PREVAL H, SOUTHARD R. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents:case-control study [J]. Child Adolesc Psychiatry Ment Health 2009, 3(01).

齐拉西酮合并氯硝西泮治疗精神分裂症激越症状的研究

Study on ziprasidone combined with clonazepam in the treatment of agitation of schizophrenia

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	安彦敏,曹志然,霍绪平,赵惠芳. 银杏叶片治疗精神分裂症患者脂代谢紊乱的疗效[J]. 医学研究与教育, 2020, 37(1): 20-25.
[2]	崔彦龙,严保平,孙秀丽,成玉敏,曹志然. 氨磺必利与利培酮治疗阴性症状为主精神分裂症疗效及安全性对照研究[J]. 医学研究与教育, 2018, 35(6): 42-47.
[3]	王一鑫,张云淑,栗克清. 精神分裂症患者生活质量的影响因素研究进展[J]. 医学研究与教育, 2018, 35(5): 49-54.